Vistagen regains full compliance with nasdaq listing requirements

South san francisco, calif.--(business wire)---- $vtgn #mentalhealth--vistagen (nasdaq: vtgn), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (cns) disorders, today announced that, on june 22, 2023, vistagen received a letter from the listing qualifications staff of the nasdaq stock market, llc (nasdaq) indicating that vistagen has regained full compliance with the minimum $1.00 bid price per s.
VTGN Ratings Summary
VTGN Quant Ranking